| 產品名稱 | JVM-2 |
|---|---|
| 商品貨號 | B196847 |
| Organism | Homo sapiens, human |
| Tissue | peripheral blood |
| Cell Type | lymphoblast; immortalized with Epstein-Barr virus (EBV); Epstein-Barr virus (EBV) transformed |
| Product Format | frozen |
| Morphology | lymphoblast |
| Culture Properties | suspension |
| Biosafety Level | 2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease | Mantle Cell Lymphoma |
| Age | 63 |
| Gender | female |
| Ethnicity | Caucasian |
| Storage Conditions | liquid nitrogen vapor phase |
| Karyotype | Bimodal chromosome number: 46 and 92This is a bimodal female cell line with approximately half the cells being pseudodiploid and the other half pseudotetraploid. Most cells contain the t(11;14)(q13;q32) derivative chromosome common to Mantle Cell Lymphoma. Other derivative chromosomes included: t(3;8)(q13;p21), add(4q) [or t(4;13)(q2?5;q1?4)], del(13)(q21) and dup(16p). |
| Images |  |
| Derivation | Leukemic cells from a patient with B-prolymphocytic leukemia were immortalized in vitro with Epstein-Barr virus (EBV) in the presence of phorbol-ester, TPA. |
| Clinical Data | 63 Caucasian female Leukemic cells from a patient with B-prolymphocytic leukemia were immortalized in vitro with Epstein-Barr virus (EBV) in the presence of phorbol-ester, TPA. JVM-2 is characterized cytogenetically by t(11;14)(q13; q32) [PubMed: 3093393 and 3262465]. |
| Antigen Expression | CD3-, CD5-, CD10-, CD19+, CD20+, CD23+ (verified at ATCC) |
| Oncogene | p53 [PubMed: 16434365] |
| Genes Expressed | p53 Ref   Salaverria I, et al. Mantle cell lymphoma: from pathology and molecular pathogenesis to new therapeutic perspectives. Haematologica 91: 11-16, 2006. PubMed: 16434365,CD3-, CD5-, CD10-, CD19+, CD20+, CD23+ (verified at ATCC) |
| Comments | JVM-2 is characterized cytogenetically by t(11;14)(q13; q32) Ref |
| Complete Growth Medium | The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing | Cultures can be maintained by addition of fresh medium every 2 to 3 days (depending on cell density). Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 x 104 to 3 x 104 viable cells/mL. Do not allow the cell concentration to exceed 1 X 106 cells/mL. |
| Cryopreservation | 70% growth medium; 20% FBS; 10% DMSO |
| Culture Conditions | Temperature: 37°C
Atmosphere: air, 95%; carbon dioxide (CO2), 5% |
| STR Profile | Amelogenin: X CSF1PO: 11 D13S317: 11,13 D16S539: 12,13 D5S818: 11,12 D7S820: 10,11 THO1: 6,9 TPOX: 8,11 vWA: 17 |
| Population Doubling Time | about 48 hours |
| Name of Depositor | J.V.Melo |
| References | Melo JV, et al. Two new cell lines from B-prolymphocytic leukaemia: characterization by morphology, immunological markers, karyotype and Ig gene rearrangement. Int. J. Cancer 38: 531-538, 1986. PubMed: 3093393 Salaverria I, et al. Mantle cell lymphoma: from pathology and molecular pathogenesis to new therapeutic perspectives. Haematologica 91: 11-16, 2006. PubMed: 16434365 de Leeuw RJ, et al. Comprehensive whole genome array CGH profiling of mantle cell lymphoma model genomes. Hum Mol Genet.: 1;13(17):1827-37 ( 2004). PubMed: 15229187. Tucker, C.A., et al. Four human t(11;14)(q13;q32)-containing cell lines having classic and variant features of Mantle Cell Lymphoma. Leuk Res. 30(4): 449-457, 2006. PubMed: 16183118. |
| 梅經理 | 17280875617 | 1438578920 |
| 胡經理 | 13345964880 | 2438244627 |
| 周經理 | 17757487661 | 1296385441 |
| 于經理 | 18067160830 | 2088210172 |
| 沈經理 | 19548299266 | 2662369050 |
| 李經理 | 13626845108 | 972239479 |
